Ranbaxy Laboratories

1. Mylan, Takeda Bury Hatchet In Diabetes Drug Feud

Wednesday, Mar 17, 2010

Mylan Inc. has resolved two patent infringement suits brought by Takeda Pharmaceutical Co. Ltd. over plans to market generic versions of diabetes drugs Actos and Actoplus Met.

2. Ranbaxy, Takeda Strike Licensing Deal Over Actos

Monday, Mar 15, 2010

Ranbaxy Laboratories Ltd. has agreed to license Takeda Pharmaceutical Co. Ltd.'s Actos patents in order to end a protracted legal battle and bring a generic version of the blockbuster diabetes treatment to market.

3. OxyContin Buyers Resolve Purdue Antitrust Claims

Monday, Mar 08, 2010

Six plaintiffs seeking to certify indirect purchaser classes in multidistrict litigation accusing Purdue Pharma LP of excluding generic competition for the painkiller OxyContin by engaging in sham patent infringement litigation have resolved their claims with the drugmaker.

4. AstraZeneca Slaps Sun Pharma Over Nexium IV Generic

Tuesday, Mar 02, 2010

AstraZeneca AB has hit generic-drug maker Sun Pharma Global Inc. with a patent suit over its plan to market a generic formulation of AstraZeneca’s intravenous acid reflux disease treatment Nexium IV.

5. Ortho, Braun Marked Drugs With Expired Patents: Suits

Tuesday, Mar 02, 2010

A retired Philadelphia doctor has sued Ortho-McNeil-Janssen Pharmaceuticals Inc. and B. Braun Medical Inc. alleging they falsely marked medical supplies and drugs — including schizophrenia treatment Risperdone — as patented.

6. Medicis Sues Lupin To Halt Generic Acne Drug

Wednesday, Feb 03, 2010

Skin health specialist Medicis Pharmaceutical Corp. has hauled Lupin Ltd. into court over the Indian drugmaker's plan to manufacture generic versions of all five approved dosages of acne drug Solodyn.

7. Cephalon To Buy Swiss Drugmaker Mepha For $590M

Monday, Feb 01, 2010

Cephalon Inc. has agreed to pay about $590 million (622.5 million Swiss francs) for the privately held Swiss pharmaceutical company Mepha AG, the companies announced Monday.

8. Supreme Court Won't Take On Omnicef Patent Case

Monday, Jan 11, 2010

In a setback for drug companies trying to enforce broad interpretations of their patents, the U.S. Supreme Court on Monday declined to hear Astellas Pharma Inc.'s case against generic-drug makers that allegedly infringed a patent for the drug Omnicef.

9. AstraZeneca, Teva Settle Heartburn Drug Patent Suits

Thursday, Jan 07, 2010

AstraZeneca AB and Teva Pharmaceuticals Ltd. have settled patent litigation over the Israeli generic-drug maker's versions of blockbuster heartburn medications Nexium and Prilosec, according to the companies.

10. Cephalon Deals Went Beyond Provigil: Direct Buyers

Wednesday, Jan 06, 2010

Direct purchaser plaintiffs suing Cephalon Inc. and several generic-drug makers for striking allegedly illegal deals to keep a copycat version of narcolepsy drug Provigil off the market have filed an amended complaint that they say identifies more anti-competitive and illegal aspects of the settlements at issue.

11. Ranbaxy Admits To Infringing Purdue OxyContin Patent

Monday, Dec 07, 2009

Ranbaxy Pharmaceuticals Inc. has admitted to infringing a Purdue Pharma LP patent for the painkiller OxyContin in a consent order resolving Purdue's suit, which had been tied to antitrust multidistrict litigation accusing Purdue of excluding generic competition for the drug through sham litigation.

12. Knobbe Martens Nabs Ex-Ranbaxy VP Of Global IP

Tuesday, Nov 10, 2009

Knobbe Martens Olson & Bear LLP has lured a senior intellectual property executive from Ranbaxy Laboratories Ltd. to bolster the firm's offerings in the generic pharmaceutical industry.

13. Roche Appeals Ranbaxy Noninfringement Ruling

Monday, Oct 26, 2009

Roche Palo Alto LLC has decided to appeal a ruling that while its patent for Valcyte is valid, a generic version of the anti-viral drug made by Ranbaxy Laboratories Ltd. does not infringe it.

14. Impax Agrees to Settle Flomax Patent Dispute

Wednesday, Oct 07, 2009

Impax Laboratories Inc. has reached an agreement with drugmakers Astellas Pharma Inc. and Boehringer Ingelheim Pharmaceuticals Inc. to settle a patent dispute related to a generic version of Flomax, a drug used to treat the symptoms of an enlarged prostate.

15. Roche Valcyte Patent Ruled Valid, But Not Infringed

Thursday, Oct 01, 2009

A judge has ruled that a Roche Palo Alto LLC patent used for the formulation of its anti-viral drug Valcyte is valid but that Ranbaxy Laboratories Ltd.’s generic version of the drug does not infringe it.

16. Eisai Urges Court To Toss Apotex Suit Over Aricept

Monday, Sep 28, 2009

Eisai Co. Ltd. has asked a federal court to dismiss Apotex Inc.’s declaratory judgment action over four patents covering Eisai’s Alzheimer’s drug Aricept, arguing that Apotex is using the suit to try to jump ahead of competitors in the approval process to market the generic drug.

17. Teva's Suit Over Aricept Infringement Tossed

Friday, Sep 11, 2009

A federal judge has dismissed a declaratory judgment suit filed by Teva Pharmaceuticals Inc. and its Gate Pharmaceuticals division seeking a determination that they did not infringe four patents covering Eisai Co. Ltd.'s blockbuster Alzheimer's drug Aricept.

18. Cephalon Tries To Quash FTC Pay-For-Delay Suit

Tuesday, Sep 01, 2009

Cephalon Inc. has asked a federal judge to dismiss the Federal Trade Commission's ongoing antitrust suit alleging that the drugmaker illegally paid off generics competitors in a reverse payment agreement over the patent for narcolepsy drug Provigil.

19. Walgreen Hits Cephalon Over Provigil Generic Deals

Monday, Aug 31, 2009

Walgreen Co., Safeway Inc. and three others have become the latest retailers to accuse Cephalon Inc. of striking illegal deals with generic-drug makers to keep a copycat version of narcolepsy drug Provigil off the market.

20. Rite Aid, CVS Hit Cephalon With New Provigil Suit

Friday, Aug 21, 2009

Pharmacy chains including Rite Aid Corp. and CVS Caremark Corp. have waded into the antitrust litigation against Cephalon Inc., filing a complaint over the pharmaceutical company's alleged conspiracy with generics makers to keep narcolepsy drug Provigil off the market.